Could We Predict the Response of Immune Checkpoint Inhibitor Treatment in Hepatocellular Carcinoma?

SIMPLE SUMMARY: The use of anti-programmed cell-death protein (ligand)-1 (PD-[L]1) is now a standard of care for treating hepatocellular carcinoma (HCC). However, the treatment only benefits 10–20% of patients when used as a monotherapy. The unique environments of hepatitis and/or cirrhosis, which c...

Descripción completa

Detalles Bibliográficos
Autores principales: Lee, Choong-kun, Chan, Stephen L., Chon, Hong Jae
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9264773/
https://www.ncbi.nlm.nih.gov/pubmed/35804984
http://dx.doi.org/10.3390/cancers14133213

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9264773/
https://www.ncbi.nlm.nih.gov/pubmed/35804984
http://dx.doi.org/10.3390/cancers14133213

Ejemplares similares